Search Results

Avinger, Inc. today announced that it will increase focus on its coronary artery disease program, where it is developing an innovative new image-guided therapeutic system to address unmet coronary market needs, while reducing the operating costs of its peripheral artery disease business.

Avinger, Inc., a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, reported results for the first quarter ended March 31, 2024.

Avinger, Inc. today announced that it will release its financial results for the first quarter 2024 after the close of trading on Wednesday, May 15, 2024.

Avinger, Inc. announced the conversion of $11 million or approximately 80% of its existing debt with entities affiliated with CRG Partners III L.P. into a shares of a new series of convertible preferred stock.

Avinger, Inc. announced the closing its previously announced public offering of an aggregate of 3,614,457 shares of its common stock, Series A-1 warrants to purchase up to 3,614,457 shares of common stock, Series A-2 warrants to purchase up to 3,614,457 shares of common stock and Series A-3 warrants to purchase up to 3,614,457 shares of common stock, at a combined public offering price of $1.66 per share and accompanying Series Warrants.

Avinger, Inc. announced the pricing of a public offering of an aggregate of 3,614,457 shares of its common stock, Series A-1 warrants to purchase up to 3,614,457 shares of common stock, Series A-2 warrants to purchase up to 3,614,457 shares of common stock and Series A-3 warrants to purchase up to 3,614,457 shares of common stock, at a combined public offering price of $1.66 per share and accompanying Series Warrants.

Avinger, Inc. announced the pricing of a public offering of an aggregate of 3,614,457 shares of its common stock, Series A-1 warrants to purchase up to 3,614,457 shares of common stock, Series A-2 warrants to purchase up to 3,614,457 shares of common stock and Series A-3 warrants to purchase up to 3,614,457 shares of common stock, at a combined public offering price of $1.66 per share and accompanying Series Warrants.

Avinger, Inc. today announced that it will release its financial results for the fourth quarter and full year 2023 after the close of trading on Wednesday, March 20, 2024.

Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the fourth quarter and full year ended December 31, 2023.